Chronic Myeloid Leukemia Clinical Trials For Glivec® | CML Alliance
CML Alliance
For Healthcare Professionals Outside the US  
 
Send to a friend Print this page Change Text Size  

About CML Alliance
Treating CML
Targeted Therapies and CML
Monitoring Treatment & Response
CML Resources
CML Events
CML Clinical Trials
CML Clinical Trials in Tasigna®
CML Clinical Trials in Glivec®
Links to Information
Novartis' Commitment to the Global CML Community
CML Alliance Patient Initiative
  Access educational resources for your patients to help them better understand and manage their CML.
Learn more >

CML Targeted Therapies
  Since its development, Glivec® has been a cornerstone of therapy for CML patients.
Learn more >
 

CML Clinical Trials in Glivec®




GIST
Trial Purpose Design Study ID/
[ClinicalTrials.gov ID]
ENESTg3
Nilotinib vs current treatment in patients with gastrointestinal stromal tumors (GIST)		 Compare the efficacy and safety of nilotinib (400 mg BID) vs best supportive care with or without a tyrosine kinase inhibitor in patients with GIST who have either progressed or are intolerant to 1st- or 2nd-line treatments Treatment, Randomized, Open Label, Active Control, Parallel 
Assignment,
Safety and
Efficacy 		 CAMN107A2201

[NCT00471328]
ENESTg3
-Extension
Extension study of
nilotinib vs current
treatment in
patients with GIST 		Compare the long-term efficacy and safety of nilotinib (400 mg BID) vs best supportive care with or without a tyrosine kinase inhibitor in patients with GIST who have either progressed or are intolerant to 1st- and 2nd-line treatments Treatment, Randomized, Open Label, Active Control,
Parallel Assignment, Safety 		CAMN107A2201E1

[NCT00488150]


See European Summary of Product Characteristics

Glivec® 100 mg film coated tablets (PDF)

Glivec® 400 mg film coated tablets (PDF)

Glivec® 50 mg capsules, hard (PDF)

Glivec® 100 mg capsules, hard (PDF)


About CML Alliance | Treating CML | Targeted Therapies and CML
Monitoring Treatment & Response | CML Resources | CML Events
CML Clinical Trials | Novartis' Commitment to the Global CML Community

Contact | Site Map | Privacy
Use of this website is subject to our Terms of Use

Disclaimer: This site is intended to provide information to healthcare professionals outside the United States. Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local Novartis company for local prescribing and any other information you may be interested in.
 
Novartis Oncology
 

© 2010 Novartis AG